Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Edelman

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2022
New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 DiabetesDavid Kerr, Steven Edelman, Giacomo Vespasiani, et al.
Scientific Reports|March 15, 2025
Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeuticsMike Grady, Elizabeth Holt, Hilary Cameron, et al.
Diabetes/Metabolism Research and Reviews|October 29, 2015
The past, present, and future of basal insulinsJeremy Pettus, Tricia Santos Cavaiola, William V Tamborlane, et al.
Osteopathic Medicine and Primary Care|April 24, 2007
A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetesSteven Edelman, George Dailey, Thomas Flood, et al.
Postgraduate Medicine|January 17, 2013
Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric bandingSteven Edelman, Sunil Bhoyrul, Helmuth Billy, et al.
Clinical Therapeutics|July 10, 2007
Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label studyThomas Haak, Steven Edelman, Claudia Walter, et al.
The American Journal of Managed Care|March 3, 2015
Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetesGuy David, Max Gill, Candace Gunnarsson, et al.
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonistSteven Edelman, Doreen Cassarino, David Kayne, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|April 24, 2023
Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal InsulinJennifer D Goldman, Eugenio Angueira-Serrano, Jeffrey S Gonzalez, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2023
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)Steven Edelman, Jennifer Goldman, Daniel C Malone, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2022
New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 DiabetesDavid Kerr, Steven Edelman, Giacomo Vespasiani, et al.
Scientific Reports|March 15, 2025
Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeuticsMike Grady, Elizabeth Holt, Hilary Cameron, et al.
Diabetes/Metabolism Research and Reviews|October 29, 2015
The past, present, and future of basal insulinsJeremy Pettus, Tricia Santos Cavaiola, William V Tamborlane, et al.
Osteopathic Medicine and Primary Care|April 24, 2007
A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetesSteven Edelman, George Dailey, Thomas Flood, et al.
Postgraduate Medicine|January 17, 2013
Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric bandingSteven Edelman, Sunil Bhoyrul, Helmuth Billy, et al.
Clinical Therapeutics|July 10, 2007
Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label studyThomas Haak, Steven Edelman, Claudia Walter, et al.
The American Journal of Managed Care|March 3, 2015
Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetesGuy David, Max Gill, Candace Gunnarsson, et al.
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonistSteven Edelman, Doreen Cassarino, David Kayne, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|April 24, 2023
Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal InsulinJennifer D Goldman, Eugenio Angueira-Serrano, Jeffrey S Gonzalez, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2023
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)Steven Edelman, Jennifer Goldman, Daniel C Malone, et al.
Pageof 3